Doxycycline

Generic Name: Doxycycline

Brand Names: Acticlate, Adoxa, Apprilon, Atridox, Doryx, Doxy, Doxycin, Lymepak, Mondoxyne, Monodox, Morgidox, Okebo, Oracea, Periostat, Targadox, Vibramycin

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄N_₂O_₈

CAS Number: 564-25-0

Unique Ingredient Identifier: 334895S862

Background: Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.

Indication: Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria, including:

It is also used to treat infections caused by the following gram-negative microorganisms:

Associated Conditions: Acinetobacter Infections, Anthrax, Bacterial Infection caused by Enterobacter aerogenes, Bartonellosis, Brucellosis, Campylobacter Infection, Chancroid, Chlamydia Trachomatis Infection, Early Lyme Disease, Granuloma Inguinale, Infection Due to Escherichia Coli, Inhalational Anthrax, Klebsiella Infections, Lymphogranuloma Venereum, Malaria caused by Plasmodium falciparum, Nongonococcal urethritis, Plague caused by Yersinia pestis, Psittacosis, Rectal infection caused by Chlamydia Trachomatis, Relapsing fever caused by Borrelia recurrentis, Respiratory Tract Infection Bacterial, Rickettsial infectious disorders, Severe Acne, Sexually Transmitted Infections (STIs), Shigella Infection, Trachoma inclusion conjunctivitis, Tularemia, Vibrio Cholerae Infection, Acute Intestinal amebiasis, Susceptible Bacterial Infections, Uncomplicated endocervical infection, Uncomplicated urethral infection

Clinical Trials

An Oral Doxycycline Regimen to Prevent Bacteremia Following Dental Procedures

Phase 4

Not yet recruiting

Conditions: Bacteremia
Endocarditis

Interventions: Drug: Clindamycin
Drug: Doxycycline

First Posted Date: 2024-05-20

Last Posted Date: 2024-06-17

Lead Sponsor: University of Santiago de Compostela

Target Recruit Count: 150

Registration Number: NCT06422221

Locations: 🇪🇸
Santiago de Compostela University Hospital, Santiago De Compostela, A Coruña, Spain

Randomized Directly Observed Therapy Study to Interpret Clinical Trials of Doxy-PEP

Early Phase 1

Recruiting

Conditions: Sexually Transmitted Diseases, Bacterial

Interventions: Drug: Doxycycline Pill

First Posted Date: 2024-05-16

Last Posted Date: 2025-03-10

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 48

Registration Number: NCT06414408

Locations: 🇺🇸
University of California, San Francisco/San Francisco General Hospital, San Francisco, California, United States

Doxycycline in Type II Diabetes

Phase 1

Recruiting

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Sitagliptin 100mg
Drug: Doxycyclin

First Posted Date: 2024-03-26

Last Posted Date: 2025-04-04

Lead Sponsor: Mostafa Bahaa

Target Recruit Count: 60

Registration Number: NCT06329882

Locations: 🇪🇬
Tanta Unuversity, Tanta, Egypt

In-vivo Transmission Model in Semi-immune Adults

Phase 1

Not yet recruiting

Conditions: Controlled Human Malaria Infection
Induced Blood Stage Malaria Infection
Malaria Transmission
Malaria Challenge

Interventions: Drug: Piperaquine tablets , which will be administered orally as a single dose of 480mg (320mg+160mg).
Drug: Doxycycline (100mg tablets strength as Doxycycline Hyclate) will also be administered orally and will be given as 1 tablet (100mg) Once daily for 7 days.

First Posted Date: 2023-12-15

Last Posted Date: 2023-12-15

Lead Sponsor: Ifakara Health Institute

Target Recruit Count: 24

Registration Number: NCT06172686

Locations: 🇹🇿
Ifakara Health Institute, Pwani, Tanzania

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Phase 2

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Amivantamab IV
Drug: Amivantamab SC
Drug: Lazertinib
Drug: Doxycycline
Drug: Minocycline
Drug: Clindamycin
Drug: Chlorhexidine
Other: Noncomedogenic skin moisturizer
Other: Ruxolitinib
Other: Tacrolimus

First Posted Date: 2023-11-07

Last Posted Date: 2025-04-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 300

Registration Number: NCT06120140

Locations: 🇹🇷
Adana City Hospital, Adana, Turkey
🇹🇷
Gulhane Training and Research Hospital, Ankara, Turkey
🇨🇳
Sichuan Cancer Hospital, Chengdu, China

and more 90 locations

Cefixime Plus Doxycycline Compared to Ceftriaxone Plus Azithromycin for Treatment of Gonorrhoea

Phase 4

Completed

Conditions: Gonorrhea

Interventions: Drug: Ceftriaxon
Drug: Cefixime
Drug: Doxycyclin
Drug: Azithromycin

First Posted Date: 2023-10-19

Last Posted Date: 2023-10-23

Lead Sponsor: Bulovka Hospital

Target Recruit Count: 161

Registration Number: NCT06090565

Locations: 🇨🇿
University Hospital Bulovka, Prague, Czechia
🇨🇿
Venereology Prague, Medicentrum Beroun, Prague, Czechia

Comparisons of Treatment Responses of Early Syphilis to Benzathine Penicillin G With or Without Doxycycline

Not Applicable

Not yet recruiting

Conditions: Early Syphilis, Latent, Serological Relapse After Treatment

Interventions: Drug: Benzathine Penicillin G
Drug: Doxycycline Capsule

First Posted Date: 2023-10-05

Last Posted Date: 2023-10-05

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 688

Registration Number: NCT06069141

Locations: 🇨🇳
National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan
🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳
Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

and more 6 locations

Postexposure Prophylaxis With Single Dose Doxycycline for the Prevention of Tick-borne Relapsing Fever

Not Applicable

Not yet recruiting

Conditions: Relapsing Fever, Tick-Borne

Interventions: Drug: administration of single dose of doxycycline

First Posted Date: 2023-09-21

Last Posted Date: 2024-03-13

Lead Sponsor: Medical Corps, Israel Defense Force

Target Recruit Count: 526

Registration Number: NCT06045481

Treatment Responses of Early Syphilis to Ceftriaxone Plus Doxycycline

Phase 4

Recruiting

Conditions: Early Syphilis

Interventions: Drug: Doxycycline
Drug: Ceftriaxone
Drug: benzathine penicillin G

First Posted Date: 2023-08-08

Last Posted Date: 2023-08-08

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 300

Registration Number: NCT05980871

Locations: 🇨🇳
Kuan-Yin Lin, Taipei, Taiwan

Rickettsia Clearance Study

Phase 2

Recruiting

Conditions: Infectious Disease
Therapeutics

Interventions: Drug: Doxycyclin
Drug: Azithromycin

First Posted Date: 2023-08-02

Last Posted Date: 2024-12-27

Lead Sponsor: Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit

Target Recruit Count: 72

Registration Number: NCT05972772

Locations: 🇱🇦
Vientiane Provincial Hospital, Vientiane Province, Lao People's Democratic Republic
🇱🇦
Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Vientiane, Vientaine, Lao People's Democratic Republic

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy